Literature DB >> 16415184

B-type natriuretic peptide: a role in selection and follow up of the implantable cardioverter-defibrillator patient?

M Anderson.   

Abstract

B-type natriuretic peptide may have a role in predicting the risk of ICD therapy, identifying patients with deteriorating clinical status and allowing them to be selected for more detailed medical review and, if necessary, drug treatment.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16415184      PMCID： PMC1860760          DOI： 10.1136/hrt.2005.070888

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


  8 in total

1.  Usefulness of brain natriuretic peptide release as a surrogate marker of the efficacy of long-term cardiac resynchronization therapy in patients with heart failure.

Authors:  Anil-Martin Sinha; Karsten Filzmaier; Ole-Alexander Breithardt; Dagmar Kunz; Jürgen Graf; Kai U Markus; Peter Hanrath; Christoph Stellbrink
Journal:  Am J Cardiol       Date:  2003-03-15       Impact factor: 2.778

2.  Update of the guidelines on sudden cardiac death of the European Society of Cardiology.

Authors:  Silvia G Priori; Etienne Aliot; Carina Blomstrom-Lundqvist; Leo Bossaert; Gunter Breithardt; Pedro Brugada; John A Camm; Riccardo Cappato; Stuart M Cobbe; Carlo Di Mario; Barry J Maron; William J McKenna; Anders K Pedersen; Ursula Ravens; Peter J Schwartz; Maria Trusz-Gluza; Panos Vardas; Hein J J Wellens; Douglas P Zipes
Journal:  Eur Heart J       Date:  2003-01       Impact factor: 29.983

3.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

4.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

5.  Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies.

Authors:  A Verma; F Kilicaslan; D O Martin; S Minor; R Starling; N F Marrouche; S Almahammed; O M Wazni; S Duggal; R Zuzek; H Yamaji; J Cummings; M K Chung; P J Tchou; A Natale
Journal:  Heart       Date:  2005-05-27       Impact factor: 5.994

6.  B-type natriuretic peptide predicts sudden death in patients with chronic heart failure.

Authors:  Rudolf Berger; Martin Huelsman; Karin Strecker; Anja Bojic; Petra Moser; Brigitte Stanek; Richard Pacher
Journal:  Circulation       Date:  2002-05-21       Impact factor: 29.690

Review 7.  Risk stratification for sudden death: do we need anything more than ejection fraction?

Authors:  Alfred E Buxton
Journal:  Card Electrophysiol Rev       Date:  2003-12

8.  Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators.

Authors:  Igor Singer; Hussein Al-Khalidi; Imran Niazi; Patrick Tchou; Tony Simmons; Richard Henthorn; Michael Holroyde; Jose Brum
Journal:  J Am Coll Cardiol       Date:  2004-01-07       Impact factor: 24.094
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.